Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.40 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.40 |
| ▸ | UBE2N | P61088 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5144894 | 0.88 | TSHR (0.64) | TSHRPOLBKMT2AMEN1CTSS | |
| SCHEMBL5891355 | 0.86 | ITGB3 (0.47) | TSHRKMT2ACALCRLITGB3ITGA2B | |
| SCHEMBL5142485 | 0.86 | CALCRL (0.46) | TSHRKMT2AMEN1CALCRLITGB3 | |
| SCHEMBL5891360 | 0.85 | CALCRL (0.43) | TSHRKMT2ACALCRLITGB3ITGA2B | |
| SCHEMBL5891166 | 0.84 | CTSS (0.46) | TSHRKMT2ACTSSCTSKCALCRL | |
| SCHEMBL4677918 | 0.84 | MAPK1 (0.52) | TSHRKMT2AMEN1CTSSCTSK | |
| SCHEMBL5891753 | 0.83 | CALCRL (0.48) | TSHRKMT2AMEN1CALCRLITGB3 | |
| SCHEMBL5414325 | 0.82 | TSHR (0.64) | TSHRPOLBKMT2AMEN1CTSS | |
| SCHEMBL5891240 | 0.81 | CTSS (0.51) | TSHRKMT2ACTSSCTSKCALCRL | |
| SCHEMBL5141586 | 0.81 | CALCRL (0.49) | TSHRKMT2ACTSSCTSKCALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297706-B2 | Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disorders | ELI LILLY AND COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| US-20070072869-A1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR Xa INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | WILEY MICHAEL R | 2007-03-29 | — | — | US | disclosed |
| US-7078415-B2 | Certain glycine derivatives as factor Xa inhibitors for use in the treatment of thrombotic disorders | ELI LILLY AND COMPANY (US) | 2006-07-18 | — | — | US | disclosed |
| EP-1455787-B1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR XA INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | LILLY CO ELI (US) | 2005-06-22 | — | — | EP | disclosed |
| US-20040249155-A1 | Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders | ELI LILLY AND COMPANY | 2004-12-09 | — | — | US | disclosed |
| EP-1455787-A1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR XA INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003049735-A1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR XA INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | ELI LILLY AND COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249155-A1 | Certain glycine derivatives as factor xa inhibitors for use in the treatment of thrombotic disorders | F2, F11, SERPINC1 | TSHR 1725/4885POLB 4287/4885KMT2A 1991/4885 |
| US-20070072869-A1 | CERTAIN GLYCINE DERIVATIVES AS FACTOR Xa INHIBITORS FOR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | F2, F11, F12 | TSHR 1266/4885POLB 4361/4885KMT2A 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.